Compare Ginkgo Bioworks Holdings Inc (DNA) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Lockheed Martin Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Lockheed Martin Corporation trades at $514.99 (market cap $118.74B). The key difference: Lockheed Martin Corporation is far larger — about 201.1× Ginkgo Bioworks Holdings Inc's market cap, and Lockheed Martin Corporation pays a 2.68% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | LMT | |
|---|---|---|
Market Cap | $590.53M | $118.74B |
Sector | Health | Industrials |
52-Week High | $16.14 | $676.70 |
52-Week Low | $5.48 | $410.74 |
Enterprise Value | $627.78M | $137.54B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Lockheed Martin (LMT) trades at $520.68, down 0.49% on the day, with a bearish technical signal and mixed earnings history. The company reported $75.05B in 2025 revenue and a net income margin of 6.38%, while maintaining a $194B backlog as of Q4 2025 (24/7 Wall Street, 2026-07-13). Analyst consensus is bullish with a $614 price target, supported by strong defense spending trends.
Outlook remains positive due to robust demand from global defense budgets, but risks include execution challenges and margin pressure. The stock offers value with a P/E of 25.21 and dividend yield near 2.66%, though recent EPS misses warrant caution. Institutional sentiment favors long-term growth amid geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
